Managing elderly patients with insomnia and comorbidities can be complex. This CE/CME activity, with pharmacology credit, is designed to update primary care clinicians on treatment options and efficient clinical approaches to improve outcomes for patients.
1.00 AMA PRA Category 1 Credit™ 1.00 ANCC contact hour and 1.00 contact hour of pharmacotherapy credit
A panel discussion in eNewsletter format
Upon completion of this activity, participants will have improved their ability to:
- Apply recently developed diagnostic criteria for insomnia disorder to evaluations of older patients
- Appraise clinical evidence supporting different treatments for the management of insomnia in older patients
- Demonstrate familiarity with the safety and dosing data for medical management of insomnia in older patients
This activity has been designed to meet the educational needs of primary care physicians, nurse practitioners, and physician assistants.
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and MedEdicus LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 1.00 contact hour is provided by Postgraduate Institute for Medicine.
Designated for 1.00 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
This activity is jointly provided by Postgraduate Institute for Medicine (www.pimed.com) and MedEdicus LLC.
This activity is supported by an independent educational grant from Merck & Co., Inc.
Distributed via Practicing Clinicians Exchange.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This CE/CME activity is copyright to MedEdicus © 2017. All rights reserved. Project 126.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Larry Culpepper, MD, MPH, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consulting Fees (eg, advisory boards): Allergan; Edgemont Pharmaceuticals, LLC; H Lundbeck A/S; Ironshore Pharmaceuticals; Merck & Co, Inc; Rhodes Pharmaceuticals; Shire; and Takeda Pharmaceutical Company Limited.
Tom Roth, PhD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consulting Fees (eg, advisory boards): Actelion Pharmaceuticals Ltd; Avadel Pharmaceuticals, PLC; Merck & Co, Inc; Novartis AG; PERNIX Therapeutics; Pfizer Inc; and Seq; Fees for Non-CME/CE Services Received Directly From a Commercial Interest or Their Agents (eg, speakers’ bureaus): Merck & Co, Inc.
Wendy L. Wright, MSN, APRN, ANP/FNP, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consulting Fees (eg, advisory boards): Arbor Pharmaceuticals; Merck & Co, Inc; Pfizer Inc; and Takeda Pharmaceutical Company Limited; Fees for Non-CME/CE Services Received Directly From a Commercial Interest or Their Agents (eg, speakers’ bureaus): Merck & Co, Inc; Sanofi; and Takeda Pharmaceutical Company Limited.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following MedEdicus planners and managers, Cheryl Guttman Krader, Diane McArdle, PhD, Cynthia Tornallyay, RD, MBA, CHCP, and Michelle Ong have no real or apparent conflicts of interest to report.
Disclosure of Unlabeled Use
This educational activity might contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation and Request for Credit
There are no fees for participating in and receiving CME/CE credit for this activity. During the period March 30, 2017, through March 30, 2018, participants must read the learning objectives and faculty disclosures and study the educational activity. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon successfully completing the post-test with a score of 70% or better and the activity evaluation, a certificate will be made available immediately.
Release date: March 30, 2017
Expiration date: March 30, 2018
If you are viewing this activity online, please ensure the computer you plan to use meets the following requirements:
- Operating system: Windows or Macintosh
- Media viewing: Flash Player or Adobe Reader
- Supported browsers: Microsoft Internet Explorer, Firefox, Google Chrome, Safari, and Opera
- A good Internet connection
© 2018 Practicing Clinicians Exchange. All Rights Reserved. MPCE90716